Actavis announces divestiture of branded respiratory portfolio rights in the US and Canada to focus on core strategic therapeutic categories

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Source:
    Worldwide Computer Products News (M2). 02/05/2015.
  • Additional Information
    • Abstract:
      Pharmaceutical company Actavis (NYSE:ACT) reported on Thursday the launch of an agreement to sell the rights to its branded respiratory business (Tudorza Pressair, LAS40464 & Daliresp) in the US and Canada for an initial consideration of USD600m on completion and low single-digit royalties above a certain revenue to AstraZeneca.